UY37636A - Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 - Google Patents
Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1Info
- Publication number
- UY37636A UY37636A UY0001037636A UY37636A UY37636A UY 37636 A UY37636 A UY 37636A UY 0001037636 A UY0001037636 A UY 0001037636A UY 37636 A UY37636 A UY 37636A UY 37636 A UY37636 A UY 37636A
- Authority
- UY
- Uruguay
- Prior art keywords
- cngb1
- pigmental
- retinitis
- linked
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762474409P | 2017-03-21 | 2017-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37636A true UY37636A (es) | 2018-10-31 |
Family
ID=62044771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037636A UY37636A (es) | 2017-03-21 | 2018-03-21 | Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12246072B2 (https=) |
| EP (1) | EP3600446A1 (https=) |
| JP (1) | JP7257377B2 (https=) |
| CN (1) | CN111050805B (https=) |
| AR (1) | AR111188A1 (https=) |
| AU (1) | AU2018238422B2 (https=) |
| CA (1) | CA3056211A1 (https=) |
| TW (1) | TW201902911A (https=) |
| UY (1) | UY37636A (https=) |
| WO (1) | WO2018172961A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282362B2 (en) * | 2018-10-15 | 2025-10-01 | Fond Telethon Ets | Intein proteins and their uses |
| US12605466B2 (en) * | 2019-03-04 | 2026-04-21 | University Of Florida Research Foundation, Incorporated | Enhanced human opsin promoter for rod specific expression |
| JP7663504B2 (ja) * | 2019-03-08 | 2025-04-16 | ユニベルシテ パリ－サクレー | 遺伝子置換による希少な眼疾患のための改善された治療方法 |
| CN110241202A (zh) * | 2019-06-25 | 2019-09-17 | 复旦大学附属眼耳鼻喉科医院 | 视网膜色素变性突变位点及其应用 |
| KR20220128607A (ko) | 2019-09-18 | 2022-09-21 | 인터갈락틱 테라퓨틱스, 인크. | 합성 dna 벡터 및 사용 방법 |
| JP7703543B2 (ja) * | 2020-01-17 | 2025-07-07 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療 |
| US20230174598A1 (en) * | 2020-03-18 | 2023-06-08 | University Of Florida Research Foundation, Incorporated | Modified arrestin-1 to enhance photoreceptor survival in retinal disease |
| CN111849998A (zh) * | 2020-07-29 | 2020-10-30 | 武汉纽福斯生物科技有限公司 | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
| US12071633B2 (en) * | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| CN113201556B (zh) * | 2021-05-14 | 2022-11-22 | 浙江大学 | pSOY19-ZM2载体、其制备方法及应用 |
| JP2024524600A (ja) * | 2021-07-06 | 2024-07-05 | インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル | 桿体光受容体における遺伝子の特異的発現のためのプロモーター |
| CN115820653A (zh) * | 2021-09-17 | 2023-03-21 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
| CN119432856B (zh) * | 2024-12-30 | 2025-08-12 | 云舟生物科技(广州)股份有限公司 | 核酸分子、病毒颗粒及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2140004B1 (en) * | 2007-04-12 | 2022-01-12 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Genetic suppression and replacement |
| AU2014305218B2 (en) * | 2013-08-05 | 2020-01-16 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | Recombinant AAV-Crumbs homologue composition and methods for treating LCA-8 and progressive RP |
| PL3628334T3 (pl) * | 2014-03-21 | 2023-12-18 | Genzyme Corporation | Terapia genowa w retinopatii barwnikowej |
| EP3210632B1 (en) * | 2016-02-23 | 2022-09-28 | EyeServ GmbH | Gene therapy for the treatment of a retinal degeneration disease |
-
2018
- 2018-03-21 EP EP18719652.2A patent/EP3600446A1/en active Pending
- 2018-03-21 CA CA3056211A patent/CA3056211A1/en active Pending
- 2018-03-21 US US16/495,826 patent/US12246072B2/en active Active
- 2018-03-21 AU AU2018238422A patent/AU2018238422B2/en active Active
- 2018-03-21 AR ARP180100661A patent/AR111188A1/es unknown
- 2018-03-21 UY UY0001037636A patent/UY37636A/es not_active Application Discontinuation
- 2018-03-21 CN CN201880031841.5A patent/CN111050805B/zh active Active
- 2018-03-21 TW TW107109700A patent/TW201902911A/zh unknown
- 2018-03-21 WO PCT/IB2018/051905 patent/WO2018172961A1/en not_active Ceased
- 2018-03-21 JP JP2020501858A patent/JP7257377B2/ja active Active
-
2025
- 2025-02-03 US US19/043,744 patent/US20250262328A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111050805B (zh) | 2026-04-14 |
| CN111050805A (zh) | 2020-04-21 |
| AU2018238422B2 (en) | 2025-04-03 |
| WO2018172961A1 (en) | 2018-09-27 |
| US20200030458A1 (en) | 2020-01-30 |
| US20250262328A1 (en) | 2025-08-21 |
| CA3056211A1 (en) | 2018-09-27 |
| TW201902911A (zh) | 2019-01-16 |
| EP3600446A1 (en) | 2020-02-05 |
| US12246072B2 (en) | 2025-03-11 |
| JP7257377B2 (ja) | 2023-04-13 |
| AR111188A1 (es) | 2019-06-12 |
| AU2018238422A1 (en) | 2019-10-03 |
| JP2020511167A (ja) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37636A (es) | Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 | |
| IL272105A (en) | Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| ECSP16083000A (es) | Terapia genica para la retinitis pigmentaria | |
| MX2019007873A (es) | Terapia génica para tratar la enfermedad de wilson. | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| MX2021006531A (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| PE20210473A1 (es) | Derivados de gip y usos de estos | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| BR112016019432A2 (pt) | composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina | |
| CO2021016487A2 (es) | Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| CO2020002500A2 (es) | Análogos de insulina acilados novedosos y usos de estos | |
| MX2019008621A (es) | Peptidos terapeuticos y neuroprotectores. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| BR112016016901A2 (pt) | agentes para o uso no tratamento de inflamação retinal | |
| CO2022008421A2 (es) | Promotores específicos para neuronas bipolares activadas para el suministro ocular de genes | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| DOP2017000116A (es) | Composiciones de acción prolongada de combinación y procedimientos para hepatitis c | |
| BR112017007102A2 (pt) | uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica | |
| MX2022004219A (es) | Moduladores de atf6 y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20231026 |